An interventional study of Closed-loop TMS and Conventional TMS in Methamphetamine Use Disorder, Substance Use Disorder and Cue-reactivity, sponsored by Shanghai Mental Health Center. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Shanghai Mental Health Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Substance-Related Disorders with a site in China — 7 open to participants now, 8 under way, none of them phase 3. Substance-Related Disorders · China.
Among the 19 studies in Substance-Related Disorders with a site in China, this one is the 13th largest by planned enrollment of the 16 interventional ones that give a count, is one of 4 that started in 2026, is one of 16 with no phase, and was the 16th registered.
2,242 studies on the registry are indexed under Substance-Related Disorders; 408 are open to participants now.
Browse Substance-Related Disorders studies →7 of the 19 studies in Substance-Related Disorders with a site in China are open now. Recruiting first, the newest first:
Southwest Medical University · Sites in China
Ages 18–50 · Men only · Healthy volunteers
Second Xiangya Hospital of Central South University · Sites in China
Ages 18–65
Shaanxi Normal University · Sites in China
Ages 30–60 · Healthy volunteers
Shanghai Mental Health Center · Sites in China
Ages 18–60
Wei XIA, PhD · Sites in China
Ages 14–35 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 266 Substance-Related Disorders studies recruiting now, 130 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 90 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 4 started in 2026.
This study's planned enrollment of 21 is below the median of 108 across 1,844 interventional studies indexed under Substance-Related Disorders.
Median enrollment 82 across the 16 interventional studies, 228 across the 3 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 19 has an industry lead sponsor. The 10 most frequent:
Shanghai Mental Health Center is the lead sponsor of 277 studies on the registry; 95 are open to participants now.
Shanghai Mental Health Center has 7 studies filed under Substance-Related Disorders — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 19 studies in Substance-Related Disorders with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate whether closed-loop transcranial magnetic stimulation (TMS) targeting left-dorsolateral prefrontal cortex (l-DLPFC) can improve core clinical symptoms in individuals with methamphetamine use disorder (MUD), such as cue-reactivity and impaired inhibitory control.
The main questions it aims to answer are:
Can closed-loop TMS targeting l-DLPFC significantly reduce cue-reactivity, as measured by a Visual Analog Scale (VAS) and cue-reactivity task, compared to a conventional treatment protocol and random TMS ? Does closed-loop stimulation targeting l-DLPFC enhance cognitive control, assessed by performance on the Stop Signal Task (SST), more effectively than the other stimulation modes? Researchers will compare closed-loop, conventional, and random TMS conditions targeting l-DLPFC to determine whether closed-loop yields superior symptom improvement.
Participants will:
Be randomly assigned to one of the three stimulation groups (closed-loop, conventional and random) according to a pre-generated random number table, and receive the corresponding stimulation session targeting l-DLPFC.
Undergo cue-reactivity assessment using VAS and cue-reactivity task, and complete the SST before and after each stimulation session.
The criteria were revised on the registry on Nov 2, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm will receive closed-loop TMS. Before stimulation: The researchers measure the participant's Resting Motor Threshold (RMT) and assess their craving using VAS before and after viewing a methamphetamine-related video. The participants complete SST. During the stimulation phase, participants will: First undergo a training phase, during which EEG is recorded while they perform a cue-reactivity task to identify neural signatures and calculate stimulation thresholds. Then perform the cue-reactivity task again, and real-time EEG features are used to trigger TMS in a closed-loop mode, targeting l-DLPFC. After the stimulation, participants will: The researchers again assess their craving using VAS before and after viewing the video. The participants again complete the SST. The researchers record adverse reactions and adverse events, and evaluate the blinding effect, through a Blinding Assessment Questionnaire.
Device: Closed-loop TMS
Participants in this arm will receive conventional TMS. Before stimulation: The researchers measure the participant's RMT and assess their craving using VAS before and after viewing a methamphetamine-related video. The participants complete SST. During the stimulation phase, participants will: First undergo a training phase, during which EEG is recorded while they perform a cue-reactivity task to identify neural signatures and calculate stimulation thresholds. Then receive a TMS treatment delivered at a conventional iTBS protocol, targeting l-DLPFC, and perform the cue-reactivity task again afterwards. After the stimulation, participants will: The researchers again assess their craving using VAS before and after viewing a methamphetamine-related video. The participants again complete the SST. The researchers record adverse reactions and adverse events, and evaluate the blinding effect, through a Blinding Assessment Questionnaire.
Device: Conventional TMS
Participants in this arm will receive random TMS. Before stimulation: The researchers measure the participant's Resting Motor Threshold (RMT) and assess their craving using VAS before and after viewing a methamphetamine-related video. The participants complete SST. During the stimulation phase, participants will: First undergo a training phase, during which EEG is recorded while they perform a cue-reactivity task to identify neural signatures and calculate stimulation thresholds. Then perform the cue-reactivity task again, and TMS is triggered by a random sequence unrelated to real-time EEG features, targeting l-DLPFC. After the stimulation, participants will: The researchers again assess their craving using VAS before and after viewing a methamphetamine-related video. The participants again complete the SST. The researchers record adverse reactions and adverse events, and evaluate the blinding effect, through a Blinding Assessment Questionnaire.
Device: Random TMS
Participants receive theta burst stimulation (TBS) targeting l-DLPFC, triggered by real-time EEG signals recorded during a cue-reactivity task. This closed-loop protocol aims to deliver stimulation precisely during neural states associated with cue-induced craving.
Also known as: EEG-TMS, Closed-loop TBS, EEG triggered TMS
Participants receive TBS targeting l-DLPFC, delivered at a standard iTBS protocol (3-pulse 50-Hz bursts given at every 200 ms (i.e. at 5 Hz), 2s on and 8s off, with 1200 pulses in total), without EEG or task engagement.
Participants receive TBS targeting l-DLPFC, triggered by a random sequence unrelated to real-time EEG features.
Cue-Induced Neural Reactivity During Before and After Stimulation
EEG signals will be recorded while participants perform a cue-reactivity task during both the training phase (no stimulation) and the stimulation phase (with TMS). The primary outcome will be changes in cue-induced neural reactivity, defined by EEG features in response to methamphetamine-related cues identified in previous studies, which are also implemented to trigger stimulation in this trial. Comparisons will be made across phases (pre- vs. during stimulation) and stimulation conditions (closed-loop, conventional, random).
Time frame: During cue-reactivity task in training and stimulation phases of each session.
Change in Cue-Induced Craving Measured by Visual Analog Scale (VAS)
Participants will rate their craving levels after viewing methamphetamine-related videos using a Visual Analog Scale (VAS), ranging from 0 (no craving) to 100 (maximum craving). Craving scores will be recorded immediately before and after each stimulation session under all three stimulation conditions.
Time frame: Before and within 30 minutes after stimulation
Change in Inhibitory Control Assessed by Stop Signal Task (SST)
Participants will complete the Stop Signal Task (SST) before and after each stimulation session. Measures such as Stop Signal Reaction Time (SSRT) will be used to assess changes in inhibitory control performance across different stimulation conditions.
Time frame: Before and within 30 minutes after stimulation
Start is estimated for Oct 2026; primary completion for Oct 2026, 0 months later.
Of 819 non-industry interventional studies with no phase under Substance-Related Disorders, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 53. This study's planned 0 months is below that.
Counting every sponsor, half of 859 studies reached it within 34 months; a quarter within 17 and three quarters within 53.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: start Aug 2026 → Oct 2026 and primary completion Sep 2026 → Oct 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Mental Health Center →